Meningococcal Vaccine in Mali and Gambia

• Published in: The New England journal of medicine Vol. 389; no. 6; pp. 577 - 578
• Main Authors: Griffin, David W.J., Hoy, Jennifer F., McMahon, James H., Clarke, Ed, Alderson, Mark R., Tapia, Milagritos D.
• Format: Journal Article
• Language: English
• Published: Boston Massachusetts Medical Society 10-08-2023
• Subjects: Acquired immune deficiency syndrome; AIDS; Conflicts of interest; HIV; Human immunodeficiency virus; Humoral immunity; Immune response; Immune system; Infections; Vaccines; Gambia; Mali
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMc2307375

To the Editor:
Haidara et al. (May 25 issue)
1
report that the immune responses with the NmCV-5 vaccine were noninferior to those with the licensed MenACWY-D vaccine, a result that may allow licensing of the NmCV-5 vaccine for wider use. The results of this trial are important, given the additional humoral immunity shown against serogroup X isolates of
Neisseria meningitidis
and the potential affordability of this pentavalent vaccine.
1
The prevalence of human immunodeficiency virus (HIV) infection in Gambia and Mali (approximately 1%) is low as compared with that in other countries in Africa but is considered to be high according . . .